An Hypothesis: Disproportion Between Cardiac Troponin and B-Type Natriuretic Peptide Levels—A High Risk and Poor Prognostic Biomarker in Patients with Fulminant Myocarditis?

Shi-Ran Yu,Chun-Ying Zhang,Wei-Jue Xiong,Jiang-Tian Chen,Jun-Xian Song,Hong Chen

DOI: https://doi.org/10.1016/j.hlc.2020.12.012

2021-01-01

Abstract:In our clinical practice, we recently found some patients with severe fulminant myocarditis (FM) who showed persistently elevated cardiac troponin (cTn) levels and “seemingly normal” B-type natriuretic peptide (BNP) level, and who subsequently progressed to poor outcomes. Indeed, this sounds contrary to conventional wisdom, but it is not an accidental phenomenon. Fulminant myocarditis is a rapidly progressive disease associated with high mortality. Recent studies have shown that patients with FM are significantly more likely to require heart transplantation than those without FM. Prompt diagnosis of FM and the institution of advanced cardiac life support will save more lives. Cardiac troponin and BNP are widely used diagnostic markers. Cardiac troponin is a specific marker of cardiac injury and its level correlates with the severity of cardiac injury. However, plasma BNP has a dual identity; it is not only a marker of cardiac pressure/volume overload, but it is also a cardioprotective factor that provides effective neurohormonal compensation to maintain homeostasis. Similar to fulminant hepatitis (characterised by diffuse inflammation and massive parenchymal cell necrosis) sometimes showing disproportion between transaminase level and bilirubin level, the disproportion between cTn and BNP levels in FM seems to be consistent with its severe histopathological changes, including diffuse infiltration of the myocardium by inflammatory cells, as well as severe cardiomyocyte injury and necrosis. Moreover, in previous studies, a lower BNP level was found to be an adverse prognostic marker in end-stage heart failure. All these findings indicate that in patients with FM with a persistently high cTn level and ominous clinical presentation, a “seemingly normal” BNP level is not a friendly signal. We hypothesise that the combination of a persistently elevated cTn level and low BNP level in patients with FM indicates worse myocardial injury and poor prognosis. In our clinical practice, we recently found some patients with severe fulminant myocarditis (FM) who showed persistently elevated cardiac troponin (cTn) levels and “seemingly normal” B-type natriuretic peptide (BNP) level, and who subsequently progressed to poor outcomes. Indeed, this sounds contrary to conventional wisdom, but it is not an accidental phenomenon. Fulminant myocarditis is a rapidly progressive disease associated with high mortality. Recent studies have shown that patients with FM are significantly more likely to require heart transplantation than those without FM. Prompt diagnosis of FM and the institution of advanced cardiac life support will save more lives. Cardiac troponin and BNP are widely used diagnostic markers. Cardiac troponin is a specific marker of cardiac injury and its level correlates with the severity of cardiac injury. However, plasma BNP has a dual identity; it is not only a marker of cardiac pressure/volume overload, but it is also a cardioprotective factor that provides effective neurohormonal compensation to maintain homeostasis. Similar to fulminant hepatitis (characterised by diffuse inflammation and massive parenchymal cell necrosis) sometimes showing disproportion between transaminase level and bilirubin level, the disproportion between cTn and BNP levels in FM seems to be consistent with its severe histopathological changes, including diffuse infiltration of the myocardium by inflammatory cells, as well as severe cardiomyocyte injury and necrosis. Moreover, in previous studies, a lower BNP level was found to be an adverse prognostic marker in end-stage heart failure. All these findings indicate that in patients with FM with a persistently high cTn level and ominous clinical presentation, a “seemingly normal” BNP level is not a friendly signal. We hypothesise that the combination of a persistently elevated cTn level and low BNP level in patients with FM indicates worse myocardial injury and poor prognosis. Fulminant myocarditis (FM) is a fatal form of myocarditis characterised by acute onset, rapid progression, and high risk of mortality (40–70%) [[1]Wang D. Jiang J. Li S. Chen Y. Hui R. Wang Y. et al.Chinese Society of Cardiology Expert Consensus Statement on the Diagnosis and Treatment of Adult Fulminant Myocarditis.Sci China Life Sci. 2019; 62: 187-202Crossref PubMed Scopus (39) Google Scholar,[2]Ammirati E. Veronese G. Bottiroli M. Wang D.W. Cipriani M. Garascia A. et al.Update on acute myocarditis.Trends Cardiovasc Med. 2020; (Epub ahead of print)Crossref PubMed Scopus (23) Google Scholar]. The condition has a devastating psychological and economic impact on affected individuals, their families, and communities. Patients with FM present with symptoms of acute myocarditis accompanied by severe acute ventricular dysfunction, life-threatening arrhythmias, clinical signs of haemodynamic compromise (hypotension, tachycardia, tachyarrhythmias—occasionally bradyarrhythmias and heart block) and can eventually develop cardiogenic shock [[3]Ali-Ahmed F. Dalgaard F. Al-Khatib S.M. Sudden cardiac death in patients with myocarditis: evaluation, risk stratification, and management.Am Heart J. 2020; 220: 29-40Crossref PubMed Scopus (20) Google Scholar,[4]Ammirati E. Veronese G. Cipriani M. Moroni F. Garascia A. Brambatti M. et al.Acute and fulminant myocarditis: A pragmatic clinical approach to diagnosis and treatment.Curr Cardiol Rep. 2018; 20: 114Crossref PubMed Scopus (42) Google Scholar]. Early recognition and risk assessment of patients with FM can guide advanced intervention and cardiac life support as life-saving measures. Assessment of cardiac biomarkers such as cardiac troponin (cTn) and B-type natriuretic peptide (BNP) is recommended to facilitate diagnosis and risk assessment [[5]Kociol R.D. Cooper L.T. Fang J.C. Moslehi J.J. Pang P.S. Sabe M.A. et al.Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association.Circulation. 2020; 141: e69-e92Crossref PubMed Scopus (179) Google Scholar]. Cardiac troponin, including cTnI and cTnT, is a troponin heterotrimeric complex located in the cardiac contractile myofibrillar protein [[6]Jaffe A.S. Troponin – past, present, and future.Curr Probl Cardiol. 2012; 37: 209-228Crossref PubMed Scopus (27) Google Scholar,[7]Torre M. Jarolim P. Cardiac troponin assays in the management of heart failure.Clin Chim Acta. 2015; 441: 92-98Crossref PubMed Scopus (12) Google Scholar]. Owing to its anatomical and genetic features, it has a high cardiac specificity [[8]Babuin L. Troponin: the biomarker of choice for the detection of cardiac injury.CMAJ. 2005; 173: 1191-1202Crossref PubMed Scopus (469) Google Scholar]. Plasma concentration of cTn is normally at a low level; the levels are affected only in the setting of myocardial damage. Therefore, it is a specific and sensitive marker of cardiac injury that is widely used for diagnostic and prognostic assessment. Moreover, the dynamic changes in cTn reflect the severity of myocardial injury. In patients with FM, a dramatic elevation in cTn level is a sign of acute myocardial damage [[9]Veronese G. Ammirati E. Cipriani M. Frigerio M. Fulminant myocarditis: characteristics, treatment, and outcomes.Anatol J Cardiol. 2018; 19: 279-286PubMed Google Scholar]. B-type natriuretic peptide is a cardiac neurohormone that is widely used for the diagnosis and risk assessment of patients with acute heart failure (HF) and congestive HF [[10]Maisel A. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.N Engl J Med. 2002; 347Crossref Scopus (2753) Google Scholar,[11]Koglin J. Pehlivanli S. Schwaiblmair M. Vogeser M. Cremer P. Vonscheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure.J Am Coll Cardiol. 2001; 38: 1934-1941Crossref PubMed Scopus (378) Google Scholar]. Previous studies have identified a dual identity of BNP as an important biomarker in the body. On the one hand, ventricular volume overload and increased filling pressure stimulates the release of BNP as a protective mechanism against myocardial injury. On the other hand, BNP has also been shown to exhibit a vasorelaxant function and to induce natriuresis; in addition, it was found to ameliorate excessive activation of the renin–angiotensin–aldosterone system (RAAS) and sympathetic nervous system (SNS) in patients with cardiovascular diseases [[12]Munagala V.K. Burnett Jr., J.C. Redfield M.M. The natriuretic peptides in cardiovascular medicine.Curr Probl Cardiol. 2004; 29: 707-769Crossref PubMed Scopus (133) Google Scholar,[13]de Lemos J.A. McGuire D.K. Drazner M.H. B-type natriuretic peptide in cardiovascular disease.Lancet. 2003; 362: 316-322Abstract Full Text Full Text PDF PubMed Scopus (886) Google Scholar]. Generally, simultaneous elevation of cTn and BNP level indicates poor prognosis in patients with myocardial injury. However, in some patients with end-stage disease who have apparently congestive presentation or high cTn level, the presence of a “seemingly normal” BNP level indicates a dismal prognosis [[14]Huang B. Shen J. Li L. Huang Y. Luo S. Effect of B-type natriuretic peptide level on long-term outcome in patients with end-stage heart failure.Am J Cardiol. 2016; 118: 383-388Abstract Full Text Full Text PDF PubMed Scopus (5) Google Scholar,[15]Sugawa S. Masuda I. Kato K. Yoshimura M. Increased levels of cardiac troponin I in subjects with extremely low b-type natriuretic peptide levels.Sci Rep. 2018; 8: 5120Crossref PubMed Scopus (12) Google Scholar]. We believe that the disproportion between a persistently elevated cTn level and low BNP level in patients with FM portends severe cardiac injury and may lead to a poor outcome (Figure 1). Specifically, our hypothesis assumes that:1.As cTn is expressed in myocardium, its elevation indicates myocyte injury or death. In FM, the level of cTn often reflects a tendency for cardiac deterioration.2.In pathological conditions, release of BNP in response to myocardial stretch or increased wall tension is not only a pathological sign, but also implies adequate activation of neurohormonal compensation. However, in extreme conditions like FM, this compensatory mechanism may be impaired and may not provide enough natriuretic hormones.3.Similar to the disproportion observed between transaminase level and bilirubin level in fulminant hepatitis, which is indicative of severe hepatic injury, the disproportion between persistently high cTn level and low BNP level in patients with FM with an ominous presentation may indicate severe cardiac injury with less functional cardiomyocytes and insufficient compensatory ability, leading to a poor prognosis. Fulminant myocarditis is an uncommon but fatal form of myocarditis characterised by acute presentation, rapid progression, and high mortality [[1]Wang D. Jiang J. Li S. Chen Y. Hui R. Wang Y. et al.Chinese Society of Cardiology Expert Consensus Statement on the Diagnosis and Treatment of Adult Fulminant Myocarditis.Sci China Life Sci. 2019; 62: 187-202Crossref PubMed Scopus (39) Google Scholar,[2]Ammirati E. Veronese G. Bottiroli M. Wang D.W. Cipriani M. Garascia A. et al.Update on acute myocarditis.Trends Cardiovasc Med. 2020; (Epub ahead of print)Crossref PubMed Scopus (23) Google Scholar]. Therefore, timely recognition, aggressive intervention, and use of ventricular assist devices appear to be particularly important. Prompt treatment is the key to save the life of patients in the acute phase. Once patients with FM get through the acute phase successfully, they have a strong likelihood of a better long-term prognosis [[3]Ali-Ahmed F. Dalgaard F. Al-Khatib S.M. Sudden cardiac death in patients with myocarditis: evaluation, risk stratification, and management.Am Heart J. 2020; 220: 29-40Crossref PubMed Scopus (20) Google Scholar]. However, owing to the non-specific and variable clinical features at presentation, identification of FM and assessment of its severity at the beginning is a key challenge; the delay in arriving at an accurate diagnosis and institution of appropriate treatment may lead to a fatal outcome [[16]Acker M.A. Mechanical circulatory support for patients with acute-fulminant myocarditis.Ann Thorac Surg. 2001; 71: S73-S76Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar]. The diagnosis of FM is not straightforward, and it is more likely to be a clinical diagnosis rather than a histological or pathological one [[17]Altesha M.A. Ni T. Khan A. Liu K. Zheng X. Circular RNA in cardiovascular disease.J Cell Physiol. 2019; 234: 5588-5600Crossref PubMed Scopus (222) Google Scholar]; therefore, the identification of clinical features or markers that may inform treatment decision-making in emergency settings is a key imperative. Cardiac troponin and BNP are well-known diagnostic and prognostic biomarkers used in clinical settings. Both cTn and BNP levels can be independently used for risk stratification and prediction of cardiovascular adverse events; however, studies have documented incremental benefit with concomitant use of both markers. In one study, both high-sensitivity TnI and BNP levels were found to independently predict new-onset major adverse cardiovascular events in patients with stable coronary artery disease [[18]Bethel M.A. Patel R.A. Merrill P. Lokhnygina Y. Buse J.B. Mentz R.J. et al.Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis.Lancet Diabetes Endocrinol. 2018; 6: 105-113Abstract Full Text Full Text PDF PubMed Scopus (346) Google Scholar]. Further, use of multiple cardiac biomarkers was found useful for risk stratification of high-risk patients with cardiovascular diseases, and helped improve clinical outcomes [[19]Wong Y.K. Cheung C.Y.Y. Tang C.S. Hai J.S.H. Lee C.H. Lau K.K. et al.High-sensitivity troponin I and B-type natriuretic peptide biomarkers for prediction of cardiovascular events in patients with coronary artery disease with and without diabetes mellitus.Cardiovasc Diabetol. 2019; 18: 171Crossref PubMed Scopus (11) Google Scholar]. Moreover, the addition of cTn in a multivariable model that included BNP and other factors was found to confer an additive benefit in predicting risk, and, when combined with clinical phenotype, helped identify patients at extremely high absolute risk. In summary, concomitant use of cTn and BNP for the assessment of cardiovascular diseases can facilitate identification of high-risk conditions [[20]Rørth R. Jhund P.S. Kristensen S.L. Desai A.S. Køber L. Rouleau J.L. et al.The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes.Eur J Heart Fail. 2019; 21: 40-49Crossref PubMed Scopus (32) Google Scholar]. Cardiac troponin I, together with cTnC and cTnT, constitute a troponin heterotrimeric complex. This troponin complex is an important part of the cardiac contractile myofibrillar protein apparatus which plays an integral role in calcium-mediated excitation–contraction coupling in the skeletal and cardiac muscles [[6]Jaffe A.S. Troponin – past, present, and future.Curr Probl Cardiol. 2012; 37: 209-228Crossref PubMed Scopus (27) Google Scholar,[7]Torre M. Jarolim P. Cardiac troponin assays in the management of heart failure.Clin Chim Acta. 2015; 441: 92-98Crossref PubMed Scopus (12) Google Scholar]. Based on the development characteristics of troponins, the type of cTnI and cTnT are replaced during growth and finally change to new isoforms that are unique to adult cardiac tissue [[7]Torre M. Jarolim P. Cardiac troponin assays in the management of heart failure.Clin Chim Acta. 2015; 441: 92-98Crossref PubMed Scopus (12) Google Scholar,[8]Babuin L. Troponin: the biomarker of choice for the detection of cardiac injury.CMAJ. 2005; 173: 1191-1202Crossref PubMed Scopus (469) Google Scholar]. This phenomenon renders cTnI and cTnT as highly specific proteins of myocardial cells and provides potent biomarkers for predicting the occurrence, development, and prognosis of cardiac disorders. It is well known that healthy individuals have low concentrations of cTnI and cTnT; dramatic changes in cTn only occur following cardiac myocyte injury. Considering that the majority of cTnT and cTnI in the cardiomyocytes are bound to the troponin complex [[21]Ju¨rgen B. Vorderwinkler K.P. Falkensammer J. Mair P. Dapunt O. Puschendorf B. et al.Different intracellular compartmentations of cardiac troponins and myosin heavy chains: a causal connection to their different early release after myocardial damage.Clin Chem. 1998; 44: 1912-1918Crossref PubMed Scopus (116) Google Scholar], detection of a high plasma level of cTn implies severe destruction of the myocardial structure. Although the clear pathophysiological process is not well characterised, it more likely represents a spectrum of changes ranging from cell death and frank necrosis with myofilament disruption to less severe and likely transient changes in the integrity and permeability of the sarcolemma membrane. This implies that irrespective of the causative factors, cardiac injury will inevitably lead to an elevated plasma level of cTn, and the level of increase reflects the severity of damage [[22]Bass A. Patterson J.H. Adams Jr., K.F. Perspective on the clinical application of troponin in heart failure and states of cardiac injury.Heart Fail Rev. 2010; 15: 305-317Crossref PubMed Scopus (7) Google Scholar]. B-type natriuretic peptide is an important cardiac neurohormone synthesised in the cardiac ventricles, which was initially discovered by Sudoh et al. in porcine brain [[23]Sudoh T. Kangawa K. Minamino N. Matsuo H. A new natriuretic peptide in porcine brain.Nature. 1988; 332: 78-81Crossref PubMed Scopus (1607) Google Scholar]. The ventricular myocytes produce preproBNP peptide (134 amino acids), which is then cleaved into proBNP (108 amino acids); subsequently, the proBNP is cleaved into BNP (32 amino acids) and the inactive N-terminal proBNP peptide (NT-proBNP; 76 amino acids) [[24]Maeda K. Tsutamoto T. Wada A. Hisanaga T. Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction.Am Heart J. 1998; 135: 825-832Crossref PubMed Scopus (711) Google Scholar]. It is well known that ventricular expansion and volume overload activates natriuretic peptide system induced increase in BNP and NT-proBNP; therefore, both these can serve as biomarkers of abnormal cardiac haemodynamics. However, unlike NT-proBNP, BNP has a beneficial bioactivity, which plays a contrary role to other compensatory neurohumoral systems such as the RAAS and/or SNS. B-type natriuretic peptide induces vasodilatation, natriuresis, and diuresis—leading to some improvement in the loading conditions of the failing heart [[11]Koglin J. Pehlivanli S. Schwaiblmair M. Vogeser M. Cremer P. Vonscheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure.J Am Coll Cardiol. 2001; 38: 1934-1941Crossref PubMed Scopus (378) Google Scholar,[12]Munagala V.K. Burnett Jr., J.C. Redfield M.M. The natriuretic peptides in cardiovascular medicine.Curr Probl Cardiol. 2004; 29: 707-769Crossref PubMed Scopus (133) Google Scholar]. In conclusion, BNP, unlike other biomarkers, has a dual identity not only as a marker of cardiovascular risk, but also as a marker of beneficial compensatory response to pressure/volume overload [[25]Ufnal M. Nowinski A. Is increased plasma TMAO a compensatory response to hydrostatic and osmotic stress in cardiovascular diseases?.Med Hypotheses. 2019; 130: 109271Crossref PubMed Scopus (19) Google Scholar]. Previous studies have demonstrated the potential pharmacological effects of BNP. In patients with systolic HF without significant symptoms, 12-week chronic subcutaneous BNP therapy was found to improve cardiac and renal function at the 12-week follow-up. These findings indicated the beneficial effects of exogenous BNP in asymptomatic systolic HF [[26]McKie P.M. Schirger J.A. Benike S.L. Harstad L.K. Slusser J.P. Hodge D.O. et al.Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure.Eur J Heart Fail. 2016; 18: 433-441Crossref PubMed Scopus (19) Google Scholar]. Besides, endogenous BNP also has a beneficial regulatory effect on some metabolic disorders. BNP is known to activate lipolysis and further decrease the risk of fat deposition in ectopic organs, including the heart; this helps prevent left ventricle dysfunction and lipotoxic cardiomyopathy in obese individuals [[27]Szczepaniak L.S. Victor R.G. Orci L. Unger R.H. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America.Circ Res. 2007; 101: 759-767Crossref PubMed Scopus (204) Google Scholar,[28]Brindley D.N. Kok B.P.C. Kienesberger P.C. Lehner R. Dyck J.R.B. Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization.Am J Physiol Endocrinol Metab. 2010; 298: E897-E908Crossref PubMed Scopus (78) Google Scholar]. Studies have also suggested that increased production of endogenous natriuretic peptide is beneficial for energy efficiency in obese patients; drugs that inhibit the degradation of natriuretic peptide were shown to be beneficial for HF [[29]McMurray J.J. Packer M. Desai A.S. Gong J. Lefkowitz M.P. Rizkala A.R. et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure.N Engl J Med. 2014; 371: 993-1004Crossref PubMed Scopus (3553) Google Scholar]. Moreover, endogenous natriuretic peptide level elevation may constitute a therapeutic strategy for ameliorating the risk of cardiovascular diseases and insulin resistance [[30]Shimizu I. Minamino T. Toko H. Okada S. Ikeda H. Yasuda N. et al.Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents.J Clin Invest. 2010; 120: 1506-1514Crossref PubMed Scopus (158) Google Scholar]. In conclusion, a modestly elevated BNP level in patients with cardiac injury is more likely to be a neurohumoral compensation and not an indicator of severe damage. This theory is in line with several reports that suggested a vasodilatory effect of BNP in the coronary artery system in humans and its beneficial effect in suppressing the progression of HF and atherosclerosis [[31]Michaels A.D. Klein A. Madden J.A. Chatterjee K. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake.Circulation. 2003; 107: 2697-2701Crossref PubMed Google Scholar,[32]Nishikimi T. Maeda N. Matsuoka H. The role of natriuretic peptides in cardioprotection.Cardiovasc Res. 2006; 69: 318-328Crossref PubMed Scopus (367) Google Scholar]. Similar to an increased BNP level, decreased BNP level has been shown to be associated with some pathological conditions. Firstly, obesity, as a major independent risk factor of cardiovascular diseases, was shown to be associated with low BNP level. Wang et al. suggested a tendency of negative correlation between obesity and low plasma BNP levels [[33]Wang T.J. Larson M.G. Levy D. Benjamin E.J. Leip E.P. Wilson P.W. et al.Impact of obesity on plasma natriuretic peptide levels.Circulation. 2004; 109: 594-600Crossref PubMed Scopus (759) Google Scholar]. Subsequently, others have also demonstrated this phenomenon. In one study, overweight patients were found to suppress BNP secretion and promote BNP clearance [[34]Date T. Yamane T. Yamashita S. Matsuo S. Matsushima M. Inada K. et al.Paradoxical clearance of natriuretic peptide between pulmonary and systemic circulation: a pulmonary mechanism of maintaining natriuretic peptide plasma concentration in obese individuals.J Clin Endocrinol Metab. 2012; 97: E14-E21Crossref PubMed Scopus (6) Google Scholar], which may enhance susceptibility to cardiovascular disorders. Diabetes is another independent risk factor for cardiovascular diseases; its primary pathological mechanism of insulin resistance also showed a correlation with low BNP level. In previous studies, insulin resistance showed a significant association with plasma pro-BNP or BNP levels in obese patients [[35]Nakatsuji H. Kishida K. Funahashi T. Nakagawa T. Shimomura I. Hyperinsulinemia correlates with low levels of plasma B-type natriuretic peptide in Japanese men irrespective of fat distribution.Cardiovasc Diabetol. 2012; 11: 22Crossref PubMed Scopus (10) Google Scholar,[36]Mizuno Y. Harada E. Katoh D. Kashiwagi Y. Morikawa Y. Nakagawa H. et al.Cardiac production of B-type natriuretic peptide is inversely related to the plasma level of free fatty acids in obese individuals – possible involvement of the insulin resistance.Endocrine J. 2013; 60: 87-95Crossref PubMed Scopus (28) Google Scholar]. Furthermore, studies have reported a link between low BNP level and development of some cardiovascular diseases. In recent studies, deficiency of BNP showed a causative association with hypertension and ischaemic heart disease [37Demidenko Z.N. Blagosklonny M.V. The purpose of the HIF-1/PHD feedback loop: to limit mTOR-induced HIF-1alpha.Cell Cycle. 2011; 10: 1557-1562Crossref PubMed Scopus (73) Google Scholar, 38Minai K. Ogawa T. Kawai M. Komukai K. Tanaka T. Ogawa K. et al.The plasma B-type natriuretic peptide levels are low in males with stable ischemic heart disease (IHD) compared to those observed in patients with non-IHD: A retrospective study.PLoS One. 2014; 9: e108983Crossref PubMed Scopus (14) Google Scholar, 39Belluardo P. Cataliotti A. Bonaiuto L. Giuffrè E. Maugeri E. Noto P. et al.Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy.Am J Physiol Heart Circ Physiol. 2006; 291: H1529-H1535Crossref PubMed Scopus (50) Google Scholar, 40Tsutsumi J. Minai K. Kawai M. Ogawa K. Inoue Y. Morimoto S. et al.Manifold implications of obesity in ischemic heart disease among Japanese patients according to covariance structure analysis: low reactivity of B-type natriuretic peptide as an intervening risk factor.PLoS One. 2017; 12: e0177327Crossref PubMed Scopus (11) Google Scholar]. In conclusion, contrary to common knowledge, a low BNP level should not be blindly linked with a low risk of cardiovascular diseases. Several studies have shown the association between low BNP level and poor prognosis. A study revealed a U-shaped relationship between BNP level and all-cause mortality in patients with dilated cardiomyopathy and end-stage HF; both BNP <400 pg/mL and >3,000 pg/mL were linked to an elevated risk of all-cause mortality in these patients. The authors suggested that low BNP level may reflect impaired neurohormonal response or altered metabolism of BNP [[14]Huang B. Shen J. Li L. Huang Y. Luo S. Effect of B-type natriuretic peptide level on long-term outcome in patients with end-stage heart failure.Am J Cardiol. 2016; 118: 383-388Abstract Full Text Full Text PDF PubMed Scopus (5) Google Scholar]. As a prognostic marker, BNP can also be used to predict the outcomes of some lifesaving treatments such as transcatheter aortic valve replacement. In a recent study, in patients with severe symptomatic aortic stenosis with preserved LVEF, an obviously low BNP level was associated with myocardial decompensatory reaction to injury, implying irreversible cardiac damage; this translated to higher all-cause mortality at 2 years after surgery, particularly cardiovascular mortality [[41]Chen S. Redfors B. O'Neill B.P. Clavel M.A. Pibarot P. Elmariah S. et al.Low and elevated B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: An analysis of the PARTNER II trial and registry.Eur Heart J. 2020; 41: 958-969Crossref PubMed Scopus (15) Google Scholar]. Furthermore, studies have shown that natriuretic peptides may “lose” their effect at some stage during the progression of advanced HF. Although the precise mechanism is not clear, neurohormonal systems in patients with severe HF are unable to induce production of adequate natriuretic hormones to support haemodynamic compensation. This may be ascribed to the lack of active BNP synthesis and/or secretion, excessive BNP down-regulation and/or clearance, or other underlying mechanisms [[42]Miller W.L. Burnett Jr., J.C. Hartman K.A. Henle M.P. Burritt M.F. Jaffe A.S. Lower rather than higher levels of B-type natriuretic peptides (NT-pro-BNP and BNP) predict short-term mortality in end-stage heart failure patients treated with nesiritide.Am J Cardiol. 2005; 96: 837-841Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar,[43]Sun T. Wang L. Zhang Y. Prognostic value of B-type natriuretic peptide in patients with chronic and advanced heart failure.Intern Med J. 2007; 37: 168-171Crossref PubMed Scopus (15) Google Scholar]. In a study, a decrease in BNP level by >30% before discharge was found to be a good prognostic indicator only if it was associated with relief in congestive signs [[44]Ruocco G. Pellegrini M. De Gori C. Franci B. Nuti R. Palazzuoli A. The prognostic combined role of B-type natriuretic peptide, blood urea nitrogen and congestion signs persistence in patients with acute heart failure.J Cardiovasc Med. 2016; 17: 818-827Crossref Scopus (13) Google Scholar]. All these findings indicate that the observed association of low BNP level with poor prognosis is not an accidental finding in extreme pathological conditions. In other words, in some severe pathological conditions, whether a seemingly normal BNP level is a friendly sign or not requires assessment of other factors such as cTn level and clinical presentation. Recent studies have consistently demonstrated that FM is a severe condition associated with high mortality. Moreover, patients with FM are more likely to require advanced cardiopulmonary support such as extracorporeal membrane oxygenation and eventually require heart transplantation than those with the non-fulminant form. This is contrary to previous studies that found a paradoxically low mortality rate in patients with FM [[45]Sharma A.N. Stultz J.R. Bellamkonda N. Amsterdam E.A. Fulminant myocarditis: Epidemiology, pathogenesis, diagnosis, and management.Am J Cardiol. 2019; 124: 1954-1960Abstract Full Text Full Text PDF PubMed Scopus (23) Google Scholar]. Fulminant myocarditis represents an extreme progression of myocarditis as it is characterised by rapid progression of haemodynamic dysfunction, such as pump failure and circulation failure. In contrast to patients with acute non-fulminant myocarditis who presented with New York Heart Association (NYHA) class II–III symptoms of heart failure, those with the fulminant form most commonly exhibited NYHA class IV symptoms of heart failure. Furthermore, multiple organ failure, including respiratory, liver, or kidney failure, also appeared in an early phase [[1]Wang D. Jiang J. Li S. Chen Y. Hui R. Wang Y. et al.Chinese Society of Cardiology Expert Consensus Statement on the Diagnosis and Treatment of Adult Fulminant Myocarditis.Sci China Life Sci. 2019; 62: 187-202Crossref PubMed Scopus (39) Google Scholar]. All these findings indicate the more severe nature of pathological changes in FM. In FM, the key pathological changes in myocardium are viral infection or related immunoreaction-induced inflammation and myocyte necrosis with myocardial oedema and fibrosis [[46]Gupta S. Markham D.W. Drazner M.H. Mammen P.P. Fulminant myocarditis.Nat Clin Pract Cardiovasc Med. 2008; 5: 693-706Crossref PubMed Scopus (138) Google Scholar]. In conclusion, as manifested by dramatically elevated cTn level [[9]Veronese G. Ammirati E. Cipriani M. Frigerio M. Fulminant myocarditis: characteristics, treatment, and outcomes.Anatol J Cardiol. 2018; 19: 279-286PubMed Google Scholar] and signs of end-organ damage, a dramatic decrease in functional myocytes is more likely in FM, which will affect BNP synthesis. Furthermore, given its multiple organ dysfunction presentation, we have reason to assume that the neurohumoral regulatory mechanisms are also likely to be impaired. In general, recognition of a “seemingly normal” BNP level is still a negative sign. B-type natriuretic peptide level was shown to be positively associated with the Framingham Risk Score, which is an assessment approach to reflect the risk of coronary heart disease in the general population [[47]Hasegawa T. Asakura M. Eguchi K. Asanuma H. Ohara T. Kanzaki H. et al.Plasma B-type natriuretic peptide is a useful tool for assessing coronary heart disease risk in a Japanese general population.Hypertens Res. 2015; 38: 74-79Crossref PubMed Scopus (10) Google Scholar]. Review of these articles showed that most of these were based on a large-sample survey and most of the subjects had stable or chronic disease with partial compensatory ability; in addition, those with severe cardiac injury are likely to have been excluded at the beginning because of the high morality and relatively low morbidity. In addition, studies have suggested that isolated low BNP level is a dangerous sign without applying a uniform standard, which makes it difficult to draw judgements. However, as the incidence of FM is relatively low but its mortality is high, it is not easy to have an adequate sample size for original clinical research, let alone randomised controlled trials. To date, there is a lack of robust clinical evidence to prove our hypothesis. Therefore, further studies are required to provide definitive proof of our hypothesis. If our hypothesis is true, i.e., if disproportion between persistently high cTn level and low BNP level in a patient with FM is indicative of severe cardiac injury, it may help to reduce the misdiagnosis rate and save more lives. Previous research has confirmed that BNP is a member of compensatory neurohumoral systems. Low BNP level may also imply poor physical condition with impaired ability to synthesise and/or secrete active BNP. In particular, in extreme pathological conditions, a seemingly normal BNP level with an unexpectedly high cTn level and poor clinical presentation may indicate the need for more aggressive intervention. In routine clinical practice, this phenomenon may not be as rare as is generally perceived. Therefore, we put forward this hypothesis to highlight this paradox, which may help to avoid misdiagnosis and missed diagnosis in these severe cases and save more lives. Further studies are required to verify the validity of this hypothesis. The phenomenon of significantly high cTn level with paradoxically low BNP level in patients with FM with severe clinical presentations may be encountered in clinical settings. These patients tend to have poor outcomes because of underestimation of the risk profile. We hypothesise that a persistently high cTn level along with a seemingly normal BNP level in patients with FM with an ominous presentation may indicate severe cardiac injury with less functional cardiomyocytes and insufficient compensatory ability, and subsequent poor prognosis.